Wednesday, September 18, 2024

Sam Fulwood III and David C. Barker

2 POSTS 0 COMMENTS
Sam Fulwood III is a fellow in the Center for Congressional and Presidential Studies at American University, where his work focuses on the intersection of race, public policy, elections, media and popular culture. David C. Barker is a professor of government (American Politics) and director of the Center for Congressional and Presidential Studies. He has published dozens of peer-reviewed journal articles in outlets such as the American Political Science Review, Journal of Politics, Public Opinion Quarterly, and many others. He has authored or coauthored three university press books: Rushed to Judgment: Talk Radio, Persuasion, and American Political Behavior (2002; Columbia University Press), Representing Red and Blue: How the Culture Wars Change the Way Citizens Speak and Politicians Listen (2012; Oxford University Press) and One Nation, Two Realities: Dueling Facts and American Democracy (under contract, expected 2018; Oxford University Press).

POPULAR

Norway reaches historic milestone as electric vehicles outnumber petrol cars for the first time

Norway’s rapid transition to electric vehicles, a global first, shows the impact of policy incentives and ambitious climate goals, setting the pace for the rest of the world.

Trump-appointed judges continue assault on workers’ rights by undermining NLRB

In a move that could reshape labor rights across the country, these judges are granting preliminary injunctions to companies that argue the NLRB’s structure violates the U.S. Constitution.

Sisyphus Trump maniacally replays 2015, with repeated, inflammatory media blitzes. But that gambit...

How many unforced errors—the Arlington cemetery mess, JD Vance, fake Ohio pet-napping and Loomer—confirm Trump as monumental scatterbrain?

Forests thrive when Indigenous people have legal stewardship of their land

The fate of intact forests is closely linked to that of Indigenous peoples.

Bernie Sanders calls out Big Pharma over exorbitant drug prices: Novo Nordisk’s $900+...

As Novo Nordisk rakes in billions, Sen. Bernie Sanders and public health advocates demand answers on why U.S. patients are charged sky-high prices for life-saving drugs like Ozempic while generics could sell for a fraction of the cost.